Kornimate/medical-research-clean huggingface dataset:
autologous dendritic cells and allogenic dendritic secretomes for patients with advanced nasopharyngeal cancer

Conditions: Nasopharyngeal Cancer

Summary: the purpose of this study is to determine the safety and potential of dendritic cells therapy and secretomes therapy for advanced nasopharyngeal cancer.

there are controlled group who receives standard medical theraphy (radiotherapy or chemoradiation), one group who receives standard medical theraphy (radiotherapy or chemoradiation) and auto-dendritic adjuvant therapy, and other group who receives standard medical theraphy (radiotherapy or chemoradiation) and allo-dendritic-secretomes adjuvant therapy and continued with auto-dendritic therapy.

Eligibility criteria:
inclusion criteria: * patients who tested positive ebv and confirmed suffering advanced nasopharyngeal cancer * patients who have partial response or stable disease or progressive disease after performed standard therapy (radiology or chemoradiation) based on recist * did not take traditional medicine in the last 2 months. * patients can understand the nature of the study and willing to sign informed consent * patients who received standard medical (radiology or chemoradiation) up to one additional therapy in the last 1 month. exclusion criteria: * patients who are pregnant, planning to pregnant, or breastfeeding * patients assessed to require chemoradiation during this study * patients who get complete score after undergo standard therapy (radiology or chemoradiation) based on the recist * patients who have autoimun reaction, eczema, allergy or allergy history, and anaphylaxis * patients who have creatinin clearance result \ 1.5x above normal, sgpt-sgot \>5x above normal * patients on immunosuppressive medications, such as corticosteroids * patients who undergo major thoracic or abdominal operation * patients on high medical risk condition due to uncontrolled infection * patients who diagnosed positive of hepatitis b, hepatitis c or human immunodeificiency virus (hiv) * patients who have concurrent congestive heart failure history and other heart disease * patients who have health conditions assessed by the doctor in charge cannot be included in this clinical trial * patients who refuse or did not participate in part or all of the research process

Keywords: dendritic cells dendritic secretomes
black cohosh extract for treatment of moderate to severe menopausal symptoms

Conditions: Menopause; Quality of Life

Summary: compare the treatment efficacy of black cohosh extract 80 mg daily and placebo for moderate to severe menopausal symptoms

compare the treatment efficacy of black cohosh extract 80 mg/day an placebo for moderate to severe menopausal symptoms with kupperman menopausal index and menqol

Eligibility criteria:
inclusion criteria: * age at least 40 years * peri or post menopause * moderate to severe menopausal symptoms (kupperman index at least 20) exclusion criteria: * use hormonal treatment or other treatments within 4 weeks * use atorvastatin azathioprine or cyclosporin within 4 weeks * bmi at least 30 kg m2 * allergic to drug or components * liver disease or abnormal liver function test * psychiatric disease * alcoholic or drug abuse * vegetarian

Keywords: menopausal symptoms menopause related quality of life black cohosh cimicifuga racemosa menqol kupperman index ki liver function tests
effects of resistant starch in a beverage on post-prandial glycemic and insulinemic responses

Conditions: Hyperglycemia, Diabetes, and Obesity

Summary: hypothesis: a beverage with a resistant starch will blunt and sustain the post-prandial rise in blood glucose and insulin concentrations compared to beverage with maltodextrin (an easily digested carbohydrate).

* about two-thirds of adults in the united states are overweight or obese which can cause adverse health consequences for those individuals. post-prandial hyperglycemia is one of these possible consequences and is associated with a higher risk for type 2 diabetes. controlling hyperglycemia is important in the prevention of the onset of diabetes and obesity. resistant starch is a dietary carbohydrate which is not completely digested in the gut and produces energy for the body to use. the investigators are interested in assessing the effects of resistant starch on postprandial blood glucose and insulin concentrations. * aim: to assess the effects of a resistant starch on post-prandial blood glucose and insulin concentrations. * hypothesis: a beverage with a resistant starch will blunt and sustain the post-prandial rise in blood glucose and insulin concentrations compared to a beverage with maltodextrin (an easily digested carbohydrate).

Eligibility criteria:
inclusion criteria: * thirty healthy men and women (aged 18-29y) will be recruited from the greater lafayette, in region with the expectation that ≥20 subjects will complete the study. subjects must weigh \>110 pounds, with a bmi between 20.0 and 29.9. exclusion criteria: * weight change \> 3kg in the past 3 months * exercising vigorously over the past 3 months as well as no exercise 3 days prior to testing day * intestinal disorders including lipid mal-absorption or lactose intolerance * abnormal liver or kidney function tests; fasting blood glucose \>100mg/dl * smoking * drinking more than 2 alcoholic drinks per day * taking lipid-lowering medications or dietary supplements affecting plasma cholesterol concentration. * subjects must not be pregnant or lactating.
everolimus and tacrolimus combination for regression of left ventricular hypertrophy in renal transplants

Conditions: Hypertrophy, Left Ventricular

Summary: clinical study with two parallel group to compare the efficacy of everolimus combination + tacrolimus in regression of left ventricular hypertrophy vs tacrolimus + mycophenolate mofetil in renal transplant patients in the maintenance phase.

a single-center, randomized, open-label, 12 months study, with two parallel group to compare the efficacy of everolimus combination + tacrolimus in regression of left ventricular hypertrophy vs tacrolimus + mycophenolate mofetil in renal transplant patients in the maintenance phase.

Eligibility criteria:
inclusion criteria: * patient's signed informed consent prior to any study-related procedure. * adult patients (\> 18 years), renal transplant recipients of more than 1 year of evolution. * patients receiving maintenance immunosuppression with tacrolimus delayed release (envarsus®) and mmf / mpa. * patients with left ventricular hypertrophy detected by cardio-nmr. * subjects with glomerular filtration rate \>30 ml/min (calculated by ckd-epi) and stable in the last two analytical determinations (variation \<20%). * no known contraindications to the use of mtor inhibitors (previous intolerance, deep vein thrombosis , pulmonary embolism, proteinuria \> 0.5 g/day) * patients with hb levels ≥ 11 gr/dl. * patients with blood pressure \<140/90 mmhg in the hospital visits or \<135/85 mmhg at home. exclusion criteria: * patient's signed informed consent prior to any study-related procedure. * adult patients (\> 18 years), renal transplant recipients of more than 1 year of evolution. * patients receiving maintenance immunosuppression with tacrolimus delayed release (envarsus®) and mmf / mpa. * patients with left ventricular hypertrophy detected by cardio-nmr. * subjects with glomerular filtration rate \>30 ml/min (calculated by ckd-epi) and stable in the last two analytical determinations (variation \<20%). * no known contraindications to the use of mtor inhibitors (previous intolerance, deep vein thrombosis , pulmonary embolism, proteinuria \> 0.5 g/day) * patients with hb levels ≥ 11 gr/dl. * patients with blood pressure \<140/90 mmhg in the hospital visits or \<135/85 mmhg at home.

Keywords: renal transplant
treatment preference and patient centered prostate cancer care

Conditions: Prostate Cancer

Summary: the purpose of this study is to develop a preference based decision aid to assess the treatment preferences of prostate cancer patients, and to analyze the interaction of treatment preferences, type of treatment received and their relationship with health related quality of life, satisfaction with care, decision regret, and psychological health of men with localized prostate cancer.

the objective is to test the comparative effectiveness of a conjoint analysis decision aid intervention compared to usual care. the investigators will identify preferred attributes of prostate cancer treatments that will help in designing a conjoint analysis decision aid to help patients weigh treatment attributes. the investigators will employ values markers to represent clusters of values for particular aspects of treatments that are valued most by individual patients. the investigators will test if the concordance between values markers and treatment received is predictive of objective outcomes and subjective outcomes. the study hypothesis is that conjoint task may help in treatment choice and prostate cancer patients whose treatment is more concordant with their values markers will have improved outcomes.

Eligibility criteria:
inclusion criteria: 1. newly diagnosed with non-metastatic prostate cancer 2. has not yet started radiation or surgery 3. provide informed consent exclusion criteria: 1. distant, metastatic prostate cancer at diagnosis 2. has already begun treatment for prostate cancer 3. unable to communicate in english

Keywords: localized prostate cancer patient preference treatment choice decision making patient centered outcomes
prevalence and predictors of osteoporosis in the beijing's urban population

Conditions: Osteoporosis

Summary: 1. to establish a bmd reference database of beijing's urban population, china. 2. to determine the prevalences and risk factors of osteoporosis and osteopenia in beijing's urban population, china. 3. to describe the 25ohd level and estimate the prevalence of vitamin d insufficiency and deficiency of beijing's urban population, china. 4. estimation of the prevalence of osteoporotic fracture (vertebral) in over age of 60 of beijing's urban population, china.

with one of the biggest populations in the world, china was heavily suffered from osteoporosis. the prevalence of osteoporosis in china even is increasing fast in recent years, which are especially notable in urban population. this change maybe due to the conditions including rapid economic growth, increase in life expectancy, and changes in lifestyle. studies in 1998 including 13 separately small samples (no more than 1000 people) from 9 provinces in china showed that the prevalence of osteoporosis and osteopenia were 5.3-6.2% and 5.8-11.2%, respectively. these estimates were higher by approximately 1% than those reported in 1995. in 2002, according to dexa results in connection with population census in 2000, xiaoguang cheng et al. took a survey in 600 people who were separately studied in previously 10 research projects and find that patients with osteoporosis account for approximately 6.97% of the total china population. although these studies have documented a remarkable increase in the prevalence of osteoporosis in china, these estimations were all based on small samples. no risk factors related with osteoporosis and osteopenia, esp. hypovitaminosis d on osteoporosis and osteopenia, have been analyzed yet. so it is impossible to make any forecast of osteoporosis or give any instruction for intervention. thus this study designed to provide current and reliable data on the prevalence of osteoporosis and osteopenia and associated risk factors correlation coefficients in the beijing's urban adult population.

Eligibility criteria:
inclusion criteria: * 20 to 79 residents in urban beijing, china. exclusion criteria:
effects of aerobic training in patients with ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: this is a randomized controlled trial with blinded assessor on the effects of aerobic exercise (walking)in patients with ankylosing spondylitis.

ankylosing spondylitis (as) is a systemic inflammatory disease that affects mainly the spine and compromises globally the physical capacity of the patients. despite new advances in pharmacological therapy, physiotherapy and exercise remain essential in the treatment of as. however, the literature lacks studies showing which types of exercises are more effective in patients with as. this is a randomized controlled trial with the objective is to evaluate the effects of aerobic training on functional capacity, mobility, disease activity, cardiopulmonary capacity and cytokine levels (tnf, il10, il6 and il1) in patients with as. the duration of the trial is 24 weeks with the first 12 weeks reserved to exercise programs. the participants will be divided in two groups. the intervention group (ig) will perform walking for 50 minutes plus global stretching 3 times a week for 12 weeks. the control group (cg) will do only stretching exercises 3 times a week for 12 weeks.

Eligibility criteria:
inclusion criteria: * diagnosis of ankylosing spondylitis according to new york modified criteria. * stable drug treatment for at least 3 months * sedentary for at least 3 months before randomization * steinbrocker class i/ii exclusion criteria: * uncontrolled systemic arterial hypertension and diabetes mellitus. * ischemic heart disease * clinically significant diseases * orthopedic surgery, such as hip arthroplasty, in the last year. * inability to walk.

Keywords: ankylosing spondylitis aerobic exercise
pregtext: feasibility of monitoring influenza vaccine safety in pregnant women using text messaging

Conditions: Pregnancy

Summary: in this study, the investigators will prospectively assess fever rates and other adverse events in pregnant women after administration of inactivated influenza vaccine (iiv) using text messaging. the investigators hypothesize that women \<20 weeks gestational age who receive iiv will be willing to enroll in a text messaging-based vaccine adverse event monitoring program and will use it to report fever in the post-vaccination period as well as continue to text pregnancy-related outcomes through the end of their pregnancy.


Eligibility criteria:
inclusion criteria: 1. are pregnant with a gestational age of \<20 weeks either by last menstrual period (lmp) and/or ultrasound 2. are at least 18 years of age 3. have a visit at a study site during the enrollment period 4. receive iiv at that visit 5. have a cell phone with text messaging capabilities 6. are english or spanish-speaking 7. are willing to report via text message through end of pregnancy exclusion criteria: 1. decision to not continue with pregnancy 2. any contraindication to receipt of inactivated influenza vaccines 3. receipt laiv (live attenuated influenza vaccine) at that visit 4. previous receipt of iiv in this pregnancy 5. presence of fever \>=100.4f at time of vaccination; 6. administration of any antipyretic in the 6-hour period prior to vaccination, 7. stated intent, at time of vaccination, to use prophylactic antipyretics before the development of a fever; 8. patient only speaks a language other than english or spanish 9. patient does not have a cell phone with text messaging 10. patient's inability to read text messages

Keywords: influenza vaccination
enteral nutrition support in children and adolescents with cancer

Conditions: Malnutrition; Cancer

Summary: context and objective: tumor and its therapy have adverse effects on the nutritional status of cancer patients, leading to nutritional support. the aim was to study enteral nutrition indications, as well as its compliance and the impact on nutritional status. design and setting: clinical trial, iop, unifesp-epm. methods: patients older than 1 year followed during anticancer therapy were included from january 2002 to january 2004. they received industrialized oral supplementation - nutren 1.0 or jr (ios) and were followed on a weekly basis and reevaluated on weeks 3, 8 and 12: at these times, if inadequate outcome was observed, tube feeding with the same supplement (tfr) was indicated.


Eligibility criteria:
inclusion criteria: * were chemotherapy, age above one year and malnutrition * a z-score of weight for height (zw/h) \< -1.0 to -2.0 in children26 and ≥ 5th to \< 15th of body mass index (bmi) in adolescents 27 were considered as mild malnutrition * a zw/h \< -2.0 in children and \< 5th of bmi in adolescents as severe, respectively.28 in adults, the world health organization (who)29 cut-off values were applied: \< 18.5 mild and \< 17 severe malnutrition. exclusion criteria: * were corticosteroid or hormonal therapy * swallowing abnormalities * parenteral or tube feeding therapy * palliative care and presence of non cancer-related diseases.

Keywords: nutritional support. cancer. malnutrition. child. adolescent
pain associated with neonatal frenotomy

Conditions: Pain

Summary: the present study sought to examine the efficacy of two oral anesthetic drugs in reducing the pain associated with neonatal frenotomy.


Eligibility criteria:
inclusion criteria: infants diagnosed with ankyloglossia at the nursery of the rhcc, who will be referred by a qualified neonatologist to the ocad for a routine tongue-tie frenotomy procedure because of breast feeding difficulties. * ankyloglossia type 1 or 2 exclusion criteria * abnormal oral or nasopharyngeal anatomy * any known congenital malformations * ankyloglossia type 3 or 4 exclusion criteria: -

Keywords: frenotomy pain
ncpap + heliox as a treatment for infant respiratory distress syndrome (rds)

Conditions: Respiratory Distress Syndrome; Bronchopulmonary Dysplasia

Summary: infants born between 28 and 32 weeks' gestation with radiological findings and clinical symptoms of moderate rds, requiring respiratory support with nasal continuous positive airway pressure (ncpap) within the first hour of life, were randomized to receive either standard medical air or a heliox/oxygen mixture 80/20 (heliox) during the first 12 hours of life, followed by medical air until ncpap was needed. the aim of the study was to assess the therapeutic effects of breathing a low-density gas mixture (heliox: 80% helium and 20% oxygen) in premature babies with respiratory distress syndrome (rds), undergoing ncpap in terms of reducing the rate of mechanical ventilation (mv).


Eligibility criteria:
inclusion criteria: * inborn infants between 28 and 32 weeks of ga * silverman score \> 5, * radiological finding of rds * a requirement of inspiratory flow of oxygen (fio2) \> 0,25 (sao2 ) between 88-95% within the first hour of life. exclusion criteria: * major congenital malformations * intraventricular hemorrhage (ivh) more than grade 2 * need of intubation in the delivery room or requirement of fio2 \>0,4 during the first hour of life.

Keywords: preterm infants nasal continuous positive airway pressure heliox bronchopulmonary dysplasia.
air optix® night and day® aqua daily wear

Conditions: Refractive Errors; Myopia; Hyperopia

Summary: the purpose of this post-market clinical follow-up (pmcf) study is to assess long term performance and safety of air optix® night and day® aqua (aonda) contact lenses in a real-world setting when worn as daily wear for vision correction.

this is a non-interventional/observational study designed as a retrospective chart review. study sites will review charts within their existing database to identify subjects who wore aonda contact lenses or purevision® 2 (pv2) contact lenses in both eyes for approximately 1 year following their contact lens examination. the data collection period consists of any approximately 1-year timeframe since and including 2009. the anticipated duration of the study is approximately 6 months.

Eligibility criteria:
inclusion criteria: * normal eyes, as determined by the investigator * at the time of the 1-year visit, subject was prescribed and wearing aonda contact lenses or pv2 contact lenses in both eyes in a daily wear modality for at least approximately 1 year without changing wear modality * baseline and 1-year visit charts available * other protocol-specified inclusion criteria may apply exclusion criteria * any recurrent history or active anterior segment infection, inflammation, abnormality, or disease contraindicating regular contact lens wear present at baseline * use of systemic or ocular medications contraindicating regular contact lens wear at baseline * history of refractive surgery or irregular cornea * other protocol-specified exclusion criteria may apply
multicenter and prospective clinical registry study of anti-n-methyl-d-aspartate receptor encephalitis in beijing area

Conditions: Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Summary: anti n-methyl-d-aspartate receptor encephalitis is an autoimmune encephalitis，found in recent years，producing the specific igg antibody induced by the nmda receptors.it is the most common curable disease among the non infectious-autoimmune encephalitis,usually has been misdiagnosed as other causes of encephalitis.our previous study found that there are differences between the chinese and the foreign in anti-nmda receptor encephalitis such as the sex ratio, the rate of combined tumor and clinical manifestations.as a new found disease,the incidence rate has been underestimated.therefore,to establish the registry research database for chinese group of anti-nmda receptor encephalitis is imminent.this study will combine beijing area's hospitals and foreign experts,depending on multicenter, prospective and registry method,to understand the incidence in beijing area,to summarize and analyze the clinical data of patients.so,there will make a solid foundation for the subsequent beijing area detection platform and other research.


Eligibility criteria:
inclusion criteria: * older than 6 months. * encephalopathy symptoms (change of mental state and consciousness level) persist for more than 24 hours; * at least one or more clinical features of the followings: fever, epilepsy, focal neurological deficiency symptoms, changes in csf(cerebrospinal fluid inflammatory), changes in eeg (electroencephalogram), radiographic abnormalities; * clinical suspected encephalitis, but conventional detected methods cannot make etiology clear exclusion criteria: * infants less than 6 months; * the metabolic encephalopathy; * infectious encephalitis with clinically clear pathogen, referring the specific pathogenic microorganisms, including: bacteria, virus, fungus, parasite, spirochete and so on; * non-infectious encephalitis with clinically clear diagnosis, including: multiple sclerosis, optic neuromyelitis, acute disseminated encephalomyelitis and so on.